Literature DB >> 7987800

Recurrent chromosome abnormalities in peripheral T-cell lymphomas.

B Schlegelberger1, A Himmler, H Bartles, R Kuse, W Sterry, W Grote.   

Abstract

Cytogenetic findings in 45 cases of peripheral T-cell lymphomas (PTL) diagnosed according to the updated Kiel classification are reported. Recurrent numerical chromosome aberrations comprised -X, -Y, -13, +X, +3, +5 and +7. Recurrent structural aberrations included t/del(1)(p31-32), t(2;5)(p23;q35), dup(5)(q23q31-32), t/dup(6q), t/del(6q), trisomy 7q, and trisomy 8q, mostly due to i(8)(q10), and changes in 14q11 and 14q32.1, mostly due to inv(14)(q11q32.1), t/del(13)(q14), t(6;7)(q13;q13), and t(13;17)(q11-13;p11). All deletions in 6q involved band 6q21 and all partial trisomies of 7q led to an amplification of band 7q21. Further studies are needed to ascertain whether these cytogenetic findings in PTL are of clinical and prognostic significance.

Entities:  

Mesh:

Year:  1994        PMID: 7987800     DOI: 10.1016/0165-4608(94)90040-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.

Authors:  Andreas Zettl; Thomas Rüdiger; Maria-Anette Konrad; Andreas Chott; Ingrid Simonitsch-Klupp; Ruth Sonnen; Hans Konrad Müller-Hermelink; German Ott
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

2.  Molecular genetic and cytogenetic analysis of a primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma.

Authors:  Keisuke Kato; Yukiko Oh; Junko Takita; Yuji Gunji; Chie Kobayashi; Ai Yoshimi; Tomohei Nakao; Mio Noma; Kazutoshi Koike; Akira Morimoto; Shigeko Iijima; Hiroshi Hojo; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2015-12-16       Impact factor: 2.490

Review 3.  Advances in the understanding and management of T-cell prolymphocytic leukemia.

Authors:  Kamel Laribi; Pierre Lemaire; Jeremy Sandrini; Alix Baugier de Materre
Journal:  Oncotarget       Date:  2017-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.